NDAORALSOLUTION
Approved
Jan 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
HICON (sodium iodide i 131) by Jubilant Therapeutics is sodium-iodide symporter (nis) protein, in thyroid follicular cells. Approved for hyperthyroidism, selected cases of carcinoma of the thyroid. First approved in 2003.
Drug data last refreshed 7h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HICON (Sodium Iodide I-131) is an oral radioactive iodine solution used to treat hyperthyroidism and select thyroid carcinomas. It works by concentrating in thyroid follicular cells via the sodium-iodide symporter, where beta emission from I-131 destroys thyroid tissue. This mechanism allows for highly selective, tissue-specific therapeutic effect.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), teams supporting this product should expect budget constraints and strategic focus on cost-efficiency and market defense rather than expansion.
Mechanism of Action
sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I) which in turn iodinates tyrosine residues of thyroglobulin (tri…
Indications (2)
Worked on HICON at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.